secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2026-09-21T20:01:07+00:00
Accession:  0001193125-26-396644
Event type: m_and_a
Sentiment:  negative
Materiality: 0.90
Item codes: 1.03, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo sells Fabry gene therapy ST-920 to PTC for $111M cash; Nasdaq delisting Sept 27
--------------------------------------------------------------------------------

- Completed Sept 17, 2026 sale of ST-920 (isaralgagene civaparvovec) to PTC Therapeutics for $111M cash at close.
- Up to $100M in additional milestone-based contingent consideration; PTC assumes specified liabilities.
- Court approved sale Sept 2, 2026 (Docket No. 426) following Aug 10 auction where PTC was successful bidder.
- Nasdaq delisting effective Sept 27, 2026 after Form 25 filed Sept 17; stock trades OTC under SGMOQ.
- Company operates as debtor-in-possession in Chapter 11 Case No. 26-10989 (Delaware Bankruptcy Court).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000119312526396644/0001193125-26-396644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000119312526396644/d178611d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-396644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer